Aeira Pte. Ltd.

Privately held: no public share price · Singapore

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaPrurigo Nodularis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
stapokibartPhase 3Atopic Dermatitis
Est. primary completion 2027-02 · NCT07106372 · CT.gov ↗
What to watch
2032 (2)
April 2032 (1)
stapokibartPhase 2/3Chronic Obstructive Pulmonary Disease
Est. primary completion 2032-04-29 · NCT06547333 · CT.gov ↗
What to watch
May 2032 (1)
stapokibartPhase 2/3Moderate to Severe Asthma
Est. primary completion 2032-05 · NCT05761028 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

March 2026Filing acceptedstapokibartNMPA accepts stapokibart application in prurigo nodularis
CN, NMPA · Keymed Biosciences · Source ↗
January 2026Filing acceptedstapokibartNMPA accepts stapokibart application in adolescent AD
CN, NMPA · Keymed Biosciences · Source ↗
28 April 2024Topline resultstapokibartPhase III PHECDA (NCT05908032) in seasonal allergic rhinitis met its primary endpoint
Keymed Biosciences Inc. · Source ↗

Financial reports

No financial reports recorded.